Myomo Inc
$ 0.80
3.88%
06 Feb - close price
- Market Cap 30,867,600 USD
- Current Price $ 0.80
- High / Low $ 0.82 / 0.76
- Stock P/E N/A
- Book Value 0.38
- EPS -0.28
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -1.00 %
- 52 Week High 6.39
- 52 Week Low 0.71
About
Myomo Inc. (MYO) is a pioneering medical robotics firm headquartered in Boston, specializing in the development of myoelectric braces designed to assist individuals with neuromuscular disorders, such as those resulting from strokes and spinal cord injuries. With its commitment to enhancing mobility and quality of life through innovative, portable robotic assistive devices, Myomo is at the forefront of transforming rehabilitation healthcare. The company combines cutting-edge robotics with advanced engineering, presenting a compelling investment opportunity for institutional investors focused on impactful health technology solutions that address critical unmet medical needs.
Analyst Target Price
$5.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-05 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-03-07 | 2023-11-07 | 2023-08-09 | 2023-05-10 | 2023-03-13 |
| Reported EPS | -0.09 | -0.12 | -0.08 | -0.01 | -0.03 | -0.03 | -0.1 | -0.07 | -0.06 | -0.04 | -0.11 | -0.29 |
| Estimated EPS | -0.11 | -0.1 | -0.1 | -0.0233 | -0.04 | -0.07 | -0.1 | -0.06 | -0.09 | -0.03 | -0.13 | -0.42 |
| Surprise | 0.02 | -0.02 | 0.02 | 0.0133 | 0.01 | 0.04 | 0 | -0.01 | 0.03 | -0.01 | 0.02 | 0.13 |
| Surprise Percentage | 18.1818% | -20% | 20% | 57.0815% | 25% | 57.1429% | 0% | -16.6667% | 33.3333% | -33.3333% | 15.3846% | 30.9524% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYO
2025-12-17 07:11:34
Myomo, Inc.'s CEO, Paul Gudonis, and CFO, David Henry, have chosen to reduce their 2026 base salaries by 10% in exchange for restricted stock units (RSUs). This decision was approved by the company's Compensation Committee and is detailed in a recent SEC filing. The RSUs will be granted in quarterly installments starting January 12, 2026, and will vest fully three months after each grant date, provided the executive remains employed.
2025-12-16 07:02:00
Myomo, Inc.'s CEO, Paul Gudonis, and CFO, David Henry, have elected to reduce their 2026 base salaries by 10% in exchange for restricted stock units (RSUs). This decision, approved by the Compensation Committee, will see them receive RSUs valued at 115% of the foregone salary, vesting quarterly starting January 12, 2026. This move follows a positive third-quarter 2025 earnings report where the company exceeded revenue and EPS expectations.
2025-11-24 10:09:50
Director Thomas Aloysius Crowley Jr. recently purchased Myomo, INC. (NYSE: MYO) shares totaling $3,232 in two transactions. This comes as Myomo's stock is near its 52-week low, despite analysts maintaining a "Strong Buy" consensus and the company reporting better-than-expected Q3 2025 earnings and revenue. The purchases signal potential insider confidence amid the stock's significant decline over the past year.
2025-11-14 21:01:00
Rosalind Advisors, Inc. significantly increased its stake in Myomo Inc. by acquiring 3,958,258 additional shares, bringing its total holdings to over 7.5 million shares. This move by the prominent investment firm, which focuses on medical and biotechnology, highlights its confidence in Myomo Inc.'s long-term potential despite the medical robotics company facing significant financial challenges and a substantial decline in stock value since its IPO. Value investors are cautioned to weigh the inherent risks against potential rewards, considering Myomo Inc.'s current financial metrics.
2025-11-14 08:09:39
Myomo Inc. announced an increase in Q3 2025 revenue to $10.1 million, up from $9.2 million year-over-year, driven by strong sales in both direct-to-patient and clinical provider channels. Despite this growth, the company reported a net loss of $3.7 million due to increased operating expenses, particularly in research and development and selling and marketing. Myomo's management aims to achieve positive cash flow and sustain operations through strategic financing and market expansion, while facing challenges in reimbursement and competitive pressures.
2025-11-13 09:08:49
Myomo, Inc. has secured a term loan of up to $17.5 million from Avenue Capital Management, aimed at supporting operations and general corporate purposes. This comes after Myomo reported a 10% revenue increase in Q3 2025, reaching $10.1 million. Despite a decrease in gross margin, the company is focused on cost reduction and strategic marketing initiatives.
